RenovoRx (RNXT) AI Stock Analysis

• Market Cap: $45.44M
• Dividend Yield: N/A
• Average Volume (3M): 303.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: 38.12%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.08
• Shares Outstanding: 36,645,885
• 10 Day Avg. Volume: 454,376
• 30 Day Avg. Volume: 303,151
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 54.45
• Enterprise Value/Gross Profit: 86.64
• Enterprise Value/Ebitda: -3.14
• 1Y Price Target: $3.50
• Price Target Upside: 182.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 49 Neutral
• Price Target: ―

RenovoRx's overall stock score reflects significant financial instability with persistent losses and negative cash flows. Despite technical analysis suggesting some short-term upward momentum, the company's valuation is weakened by a negative P/E ratio and lack of profitability. The absence of earnings call data and corporate events limits further insights into potential improvements, maintaining a cautious outlook on its stock performance.

Positive Factors

Clinical Trial Outcomes

Positive data from the first interim analysis demonstrated an overall survival of approximately 21.5 months, compared to 15.5 months in the control arm, with a favorable safety profile.

Clinical Trial Progress

The data monitoring committee (DMC) has reviewed the data and recommended continuation without changes, a positive signal.

Revenue and Financial Performance

RenovoRx reported higher revenue and a smaller net loss compared to consensus estimates for 2Q25.

Negative Factors

Earnings Report

The company reported a net loss of $0.40 per diluted share for the fourth quarter.

Financial Performance

For 1Q25, the company reported $197,000 in revenue and a net loss of $0.08 per diluted share, compared to an estimate of $335,000 and a net loss of $0.07 per diluted share.

Stock Market Reaction

RNXT shares were down on the news, likely due to deferring publication of interim data.

RenovoRx Business Overview & Revenue Model

Company Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

How the Company Makes Money

RenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.

RenovoRx Financial Statement Overview

Summary

RenovoRx is facing significant financial challenges, with persistent losses and negative cash flows. Despite improvements in revenue and equity, the company's core operations remain unprofitable, and it heavily relies on external financing. The balance sheet shows some asset management improvements, but the overall financial health is fragile, with high operational losses posing a significant risk.

Income Statement

RenovoRx shows a slight improvement in revenue with $43,000 reported in the latest year. However, the company faces a challenging profitability situation with a negative net income of $8.8 million and negative EBIT and EBITDA margins, indicating significant operational losses. The gross profit margin is also concerning as it demonstrates no cost of goods sold, which reflects no substantial revenue activities.

Balance Sheet

The balance sheet highlights a modest improvement in stockholders' equity, now at $4.48 million, up from a negative position. However, the company maintains a high leverage with a debt-to-equity ratio of 0.05, which could be considered low in relative terms but is risky in the context of negative profitability. The equity ratio is positive, indicating a shift towards better asset management, but overall financial stability remains a concern.

Cash Flow

Operating cash flow remains negative at $9.13 million, showing consistent cash outflows from operations. Free cash flow is similarly negative, reflecting the company's reliance on financing activities to sustain operations. This cash flow instability poses a risk to long-term sustainability, despite substantial financing inflows in the past year.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	662.00K	43.00K	0.00	0.00	0.00	0.00
Gross Profit	416.00K	43.00K	0.00	-6.00K	-9.00K	0.00
EBITDA	-11.49M	-10.97M	-11.39M	-9.94M	-5.66M	0.00
Net Income	-10.66M	-8.81M	-10.23M	-9.77M	-7.10M	-4.38M
Balance Sheet
Total Assets	13.64M	8.12M	1.47M	7.26M	16.29M	1.91M
Cash, Cash Equivalents and Short-Term Investments	12.31M	7.15M	1.17M	6.44M	15.19M	1.79M
Total Debt	260.00K	278.00K	0.00	0.00	0.00	2.79M
Total Liabilities	3.00M	3.64M	4.47M	1.10M	938.00K	16.57M
Stockholders Equity	10.64M	4.48M	-3.00M	6.16M	15.35M	-14.66M
Cash Flow
Free Cash Flow	-10.32M	-9.14M	-10.26M	-8.81M	-5.93M	-3.53M
Operating Cash Flow	-10.31M	-9.13M	-10.26M	-8.81M	-5.92M	-3.53M
Investing Cash Flow	-14.00K	-12.00K	2.03M	-2.03M	-15.00K	0.00
Financing Cash Flow	10.89M	15.12M	5.01M	42.00K	19.33M	3.20M

RenovoRx Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Positive. The current price of 1.24 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.18, and above the 200-day MA of 1.17, indicating a bullish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 60.69 is Neutral, neither overbought nor oversold. The STOCH value of 91.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNXT.

RenovoRx Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OVID	54 Neutral	$91.73M	―	-52.77%	―	1071.91%	-27.61%
Sector *	51 Neutral	$7.92B	-0.43	-41.67%	2.21%	22.29%	-1.85%
RNXT	49 Neutral	$45.44M	―	-107.11%	―	―	38.12%
GRCE	46 Neutral	$42.32M	―	-16.78%	―	―	32.31%
PEPG	40 Underperform	$41.98M	―	-85.69%	―	―	10.04%
JSPR	35 Underperform	$43.72M	―	-146.87%	―	―	-17.96%
NRSN	30 Underperform	$27.06M	―	-2880.11%	―	―	31.09%